Indications

Browse indications

Filter by therapy area or team. Click an indication to see the reports available by report type and market.

Therapy area
For
Oncology

NSCLC

US · In-Market
Competitive IntelligenceDisease LandscapePatient Flow ModelPayer & HTAField-Force StrategyLaunch Readiness
Competitive IntelligenceOpen →Disease LandscapeOpen →Patient Flow ModelOpen →Payer & HTAOpen →Field-Force StrategyOpen →Launch ReadinessOpen →Indication overview→
Metabolic

MASH

US · In-Market
Competitive IntelligenceDisease LandscapePayer & HTAMarket Sizing ModelLaunch Readiness
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Market Sizing ModelOpen →Launch ReadinessOpen →Indication overview→
Rare Disease

PNH

US · GCC · FR · UK · DE · In-Market
Competitive IntelligenceDisease LandscapePayer & HTALaunch ReadinessPricing Strategy ModelPatient Flow ModelMarket Sizing ModelKOL MappingHTA Strategy Model
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Competitive IntelligenceOpen →Payer & HTAOpen →Launch ReadinessOpen →Disease LandscapeOpen →Pricing Strategy ModelOpen →Payer & HTAOpen →Launch ReadinessOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Competitive IntelligenceOpen →Market Sizing ModelOpen →Launch ReadinessOpen →Competitive IntelligenceOpen →KOL MappingOpen →Market Sizing ModelOpen →Patient Flow ModelOpen →Launch ReadinessOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →Disease LandscapeOpen →Disease LandscapeOpen →Payer & HTAOpen →Market Sizing ModelOpen →Disease LandscapeOpen →Competitive IntelligenceOpen →Launch ReadinessOpen →Pricing Strategy ModelOpen →KOL MappingOpen →Market Sizing ModelOpen →Patient Flow ModelOpen →HTA Strategy ModelOpen →Payer & HTAOpen →KOL MappingOpen →Indication overview→
Immunology

Atopic Dermatitis

US · In-Market
Competitive IntelligenceDisease LandscapePayer & HTALaunch Readiness
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Launch ReadinessOpen →Indication overview→
Metabolic

Type 2 Diabetes

US · In-Market
Competitive IntelligenceDisease LandscapePayer & HTALaunch ReadinessMarket Sizing ModelPricing Strategy Model
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Launch ReadinessOpen →Market Sizing ModelOpen →Pricing Strategy ModelOpen →Indication overview→
Metabolic

Obesity

US · In-Market
Competitive IntelligenceDisease LandscapePayer & HTAPricing Strategy ModelLaunch Readiness
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Pricing Strategy ModelOpen →Launch ReadinessOpen →Indication overview→
Neurology

Alzheimer's Disease

US · In-Market
Competitive IntelligenceDisease LandscapePayer & HTALaunch Readiness
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Launch ReadinessOpen →Indication overview→
Rare Disease

IgA Nephropathy

US · GCC · UK · In-Market
Competitive IntelligenceDisease LandscapePayer & HTALaunch ReadinessPricing Strategy ModelMarket Sizing ModelPatient Flow ModelHTA Strategy ModelKOL Mapping
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Competitive IntelligenceOpen →Competitive IntelligenceOpen →Payer & HTAOpen →Launch ReadinessOpen →Launch ReadinessOpen →Pricing Strategy ModelOpen →Launch ReadinessOpen →Disease LandscapeOpen →Market Sizing ModelOpen →Disease LandscapeOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Pricing Strategy ModelOpen →HTA Strategy ModelOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →KOL MappingOpen →Payer & HTAOpen →KOL MappingOpen →Indication overview→
Rare Disease

Hereditary Angioedema

US · GCC · UK · In-Market
Competitive IntelligencePayer & HTADisease LandscapeMarket Sizing ModelLaunch ReadinessPatient Flow ModelKOL MappingPricing Strategy ModelHTA Strategy Model
Competitive IntelligenceOpen →Payer & HTAOpen →Disease LandscapeOpen →Competitive IntelligenceOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →Payer & HTAOpen →Launch ReadinessOpen →Disease LandscapeOpen →Patient Flow ModelOpen →Competitive IntelligenceOpen →Patient Flow ModelOpen →KOL MappingOpen →Pricing Strategy ModelOpen →Disease LandscapeOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →Payer & HTAOpen →HTA Strategy ModelOpen →Launch ReadinessOpen →Patient Flow ModelOpen →KOL MappingOpen →Pricing Strategy ModelOpen →Launch ReadinessOpen →Indication overview→
Rare Disease

ATTR Amyloidosis

US · UK · GCC · In-Market
Competitive IntelligenceDisease LandscapePayer & HTALaunch ReadinessPatient Flow ModelKOL MappingHTA Strategy ModelMarket Sizing ModelPricing Strategy Model
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Competitive IntelligenceOpen →Competitive IntelligenceOpen →Payer & HTAOpen →Launch ReadinessOpen →Patient Flow ModelOpen →Payer & HTAOpen →Launch ReadinessOpen →Disease LandscapeOpen →KOL MappingOpen →Launch ReadinessOpen →Patient Flow ModelOpen →HTA Strategy ModelOpen →Market Sizing ModelOpen →Patient Flow ModelOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →KOL MappingOpen →Disease LandscapeOpen →Market Sizing ModelOpen →Indication overview→
Rare Disease

Myasthenia Gravis

US · UK · GCC · In-Market
Payer & HTADisease LandscapeCompetitive IntelligenceLaunch ReadinessPatient Flow ModelHTA Strategy ModelKOL MappingMarket Sizing ModelPricing Strategy Model
Payer & HTAOpen →Disease LandscapeOpen →Competitive IntelligenceOpen →Launch ReadinessOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Disease LandscapeOpen →Launch ReadinessOpen →HTA Strategy ModelOpen →Disease LandscapeOpen →Payer & HTAOpen →Patient Flow ModelOpen →KOL MappingOpen →Launch ReadinessOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →Payer & HTAOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Competitive IntelligenceOpen →KOL MappingOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →Competitive IntelligenceOpen →Indication overview→
Rare Disease

Dravet Syndrome

US · GCC · UK · In-Market
Disease LandscapePayer & HTACompetitive IntelligenceLaunch ReadinessPatient Flow ModelKOL MappingPricing Strategy ModelHTA Strategy ModelMarket Sizing Model
Disease LandscapeOpen →Payer & HTAOpen →Competitive IntelligenceOpen →Competitive IntelligenceOpen →Launch ReadinessOpen →Patient Flow ModelOpen →Payer & HTAOpen →Disease LandscapeOpen →KOL MappingOpen →Pricing Strategy ModelOpen →HTA Strategy ModelOpen →Market Sizing ModelOpen →Launch ReadinessOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →Disease LandscapeOpen →Launch ReadinessOpen →Pricing Strategy ModelOpen →KOL MappingOpen →Pricing Strategy ModelOpen →Payer & HTAOpen →Competitive IntelligenceOpen →Indication overview→
Rare Disease

Pompe Disease

US · UK · GCC · In-Market
Disease LandscapePayer & HTACompetitive IntelligenceMarket Sizing ModelLaunch ReadinessPatient Flow ModelKOL MappingHTA Strategy ModelPricing Strategy Model
Disease LandscapeOpen →Payer & HTAOpen →Competitive IntelligenceOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →Competitive IntelligenceOpen →Launch ReadinessOpen →Disease LandscapeOpen →Launch ReadinessOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Payer & HTAOpen →Disease LandscapeOpen →Payer & HTAOpen →KOL MappingOpen →HTA Strategy ModelOpen →Launch ReadinessOpen →KOL MappingOpen →Market Sizing ModelOpen →Patient Flow ModelOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Competitive IntelligenceOpen →Indication overview→
Rare Disease

Fabry Disease

US · GCC · UK · In-Market
Competitive IntelligenceDisease LandscapePayer & HTALaunch ReadinessPatient Flow ModelPricing Strategy ModelMarket Sizing ModelKOL MappingHTA Strategy Model
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Competitive IntelligenceOpen →Launch ReadinessOpen →Competitive IntelligenceOpen →Patient Flow ModelOpen →Payer & HTAOpen →Launch ReadinessOpen →Payer & HTAOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Launch ReadinessOpen →Market Sizing ModelOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →KOL MappingOpen →Disease LandscapeOpen →Pricing Strategy ModelOpen →Disease LandscapeOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →HTA Strategy ModelOpen →KOL MappingOpen →Indication overview→
Rare Disease

Spinal Muscular Atrophy

US · UK · GCC · In-Market
Payer & HTADisease LandscapeCompetitive IntelligenceMarket Sizing ModelPatient Flow ModelLaunch ReadinessKOL MappingPricing Strategy ModelHTA Strategy Model
Payer & HTAOpen →Disease LandscapeOpen →Competitive IntelligenceOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →Competitive IntelligenceOpen →Disease LandscapeOpen →Patient Flow ModelOpen →Payer & HTAOpen →Launch ReadinessOpen →KOL MappingOpen →Disease LandscapeOpen →Payer & HTAOpen →Competitive IntelligenceOpen →Pricing Strategy ModelOpen →Launch ReadinessOpen →Market Sizing ModelOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Launch ReadinessOpen →KOL MappingOpen →HTA Strategy ModelOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Indication overview→
Rare Disease

Sickle Cell Disease

US · GCC · UK · In-Market
Disease LandscapePayer & HTACompetitive IntelligenceLaunch ReadinessPatient Flow ModelKOL MappingPricing Strategy ModelMarket Sizing ModelHTA Strategy Model
Disease LandscapeOpen →Payer & HTAOpen →Competitive IntelligenceOpen →Launch ReadinessOpen →Competitive IntelligenceOpen →Competitive IntelligenceOpen →Patient Flow ModelOpen →Payer & HTAOpen →Launch ReadinessOpen →KOL MappingOpen →Payer & HTAOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →Disease LandscapeOpen →Disease LandscapeOpen →Patient Flow ModelOpen →HTA Strategy ModelOpen →Launch ReadinessOpen →KOL MappingOpen →Patient Flow ModelOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →Indication overview→
Rare Disease

Gaucher Disease

US · In-Market
Disease LandscapeCompetitive IntelligencePayer & HTALaunch ReadinessPricing Strategy ModelMarket Sizing Model
Disease LandscapeOpen →Competitive IntelligenceOpen →Payer & HTAOpen →Launch ReadinessOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →Indication overview→
Rare Disease

Cold Agglutinin Disease

US · In-Market
Disease LandscapePayer & HTACompetitive IntelligenceLaunch ReadinessMarket Sizing ModelPricing Strategy Model
Disease LandscapeOpen →Payer & HTAOpen →Competitive IntelligenceOpen →Launch ReadinessOpen →Market Sizing ModelOpen →Pricing Strategy ModelOpen →Indication overview→
Oncology

Breast Cancer HR+/HER2-

US · UK · In-Market
Competitive IntelligenceDisease LandscapePayer & HTAKOL MappingHTA Strategy ModelLaunch ReadinessMarket Sizing ModelPricing Strategy ModelPatient Flow Model
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →KOL MappingOpen →HTA Strategy ModelOpen →Launch ReadinessOpen →Market Sizing ModelOpen →KOL MappingOpen →Pricing Strategy ModelOpen →Patient Flow ModelOpen →Indication overview→
Pulmonology

COPD

US · In-Market
Competitive IntelligenceDisease LandscapePayer & HTALaunch Readiness
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Launch ReadinessOpen →Indication overview→
Immunology

Plaque Psoriasis

US · In-Market
Competitive IntelligenceDisease LandscapePayer & HTALaunch ReadinessPricing Strategy Model
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Launch ReadinessOpen →Pricing Strategy ModelOpen →Indication overview→

Don't see your indication?

Commission any indication, comparator set and market — delivered in 72 hours.

Commission a Report